Overview
NTLA market data
Price History
NTLA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.81 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.79 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -672.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7.95 – $28.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.7B · P/B 1.55 · P/S 28.10.
Company News
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24Benzinga · Aug 7, 2026, 12:25 PM
8-K filing — Intellia Therapeutics, Inc. (NTLA)SEC EDGAR · Aug 6, 2026, 11:45 AM
Intellia Therapeutics Q2 EPS $(0.80) Misses $(0.79) Estimate, Sales $7.659M Miss $13.904M EstimateBenzinga · Aug 6, 2026, 11:06 AM
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For ThursdayBenzinga · Jul 16, 2026, 11:15 AM
Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price TargetBenzinga · Jul 16, 2026, 10:42 AM
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to GainBenzinga · Jul 10, 2026, 3:35 PM
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17Benzinga · Jul 10, 2026, 12:35 PM
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthGlobenewswire Inc · Jul 3, 2026, 11:00 AM
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)Benzinga · Jun 29, 2026, 2:40 PM